United States:
Deal On IP Rights For Biologic Drugs Under TPP Close
14 November 2016
by
Jones Day
To print this article, all you need is to be registered or login on Mondaq.com.
According to industry and congressional sources, a deal on
intellectual property rights for biologic drugs under the TPP may
be in the near future. According to recent comments from U.S. Trade
Representative Michael Froman, biologics is the last major issue
that needed to be addressed.
Read the full article on Bloomberglaw.com. (Subscription required)
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.